CA
NZ
UK
AU
IND
US
…
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Bio-Path Holdings is a clinical-stage biopharmaceutical company developing nucleic-acid therapeutics for oncology using a proprietary delivery platform. Long-term growth may be driven by progression of lead clinical candidates, regulatory approvals, and partnerships, and investors may find the company appealing if its platform produces differentiated safety or efficacy signals and it secures development funding.
Key risks include clinical and regulatory failure of unproven candidates, ongoing funding and dilution needs, and intense oncology competition that could limit commercial prospects.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -9.89M | -16.08M | -13.87M | -10.44M | -10.88M |
| Net income | -9.89M | -16.08M | -13.84M | -10.44M | -10.86M |
| Selling general administrative | 4.70M | 4.11M | 4.74M | 4.53M | 4.33M |
| Selling and marketing expenses | - | 0.12M | - | - | - |
| Gross profit | - | -0.18M | - | - | - |
| Reconciled depreciation | 0.16M | 0.18M | 0.18M | 0.16M | 0.15M |
| Ebit | - | -15.84M | -13.90M | -10.44M | -10.91M |
| Ebitda | - | -15.76M | -13.72M | -10.28M | -10.76M |
| Depreciation and amortization | - | 0.08M | 0.18M | 0.16M | 0.15M |
| Non operating income net other | - | - | - | - | 0.03M |
| Operating income | -11.99M | -15.84M | -13.90M | -10.44M | -10.91M |
| Other operating expenses | - | 15.84M | 13.90M | 10.44M | 10.91M |
| Interest expense | - | - | -0.03M | 0.00M | 0.00M |
| Interest income | 0.01M | 0.05M | 0.03M | 0.00M | 0.03M |
| Net interest income | 0.01M | 0.05M | 0.03M | 0.00M | 0.03M |
| Income tax expense | - | - | -0.03M | -0.00M | -0.03M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 11.99M | 15.84M | 13.90M | 10.44M | 10.91M |
| Cost of revenue | - | 0.18M | - | - | - |
| Total other income expense net | 2.08M | -0.23M | 0.03M | 0.00M | 0.03M |
| Net income from continuing ops | -9.89M | -16.67M | -13.87M | -10.44M | -10.88M |
| Net income applicable to common shares | - | - | - | -10.44M | -10.88M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 3.88M | 3.22M | 15.97M | 26.57M | 16.48M |
| Other current assets | - | 1.99M | 5.23M | 2.37M | 2.20M |
| Total liab | 3.73M | 2.78M | 1.80M | 1.11M | 1.41M |
| Total stockholder equity | 0.15M | 0.44M | 14.17M | 25.46M | 15.07M |
| Other current liab | - | 1.35M | 0.91M | 0.77M | 0.97M |
| Common stock | - | 0.00M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.00M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -117.50M | -107.61M | -91.53M | -77.66M | -67.22M |
| Other assets | - | 0.00M | - | - | 0.52M |
| Cash | 1.17M | 1.05M | 10.38M | 23.77M | 13.76M |
| Total current liabilities | 3.29M | 1.91M | 1.68M | 0.96M | 1.17M |
| Net debt | - | -0.94M | -10.16M | -23.54M | -13.43M |
| Short term debt | - | 0.10M | 0.11M | 0.08M | 0.09M |
| Short long term debt total | - | 0.11M | 0.22M | 0.23M | 0.33M |
| Other stockholder equity | - | 108.05M | 105.69M | 103.11M | 82.29M |
| Property plant equipment | - | - | - | 0.43M | 0.23M |
| Total current assets | 3.78M | 3.04M | 15.62M | 26.14M | 15.96M |
| Net tangible assets | - | - | - | 25.46M | 15.07M |
| Net receivables | - | 0.00M | - | - | - |
| Inventory | - | 0.00M | - | 0.52M | 1.27M |
| Accounts payable | 1.27M | 0.46M | 0.67M | 0.11M | 0.10M |
| Common stock total equity | - | - | - | - | 0.01M |
| Retained earnings total equity | - | - | - | - | -67.22M |
| Non currrent assets other | - | 0.08M | 0.16M | 0.23M | 0.29M |
| Non current assets total | 0.11M | 0.18M | 0.36M | 0.43M | 0.52M |
| Capital lease obligations | 0.08M | 0.11M | 0.22M | 0.23M | 0.33M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | - | 0.00M | -0.02M | -0.07M | - |
| Change to liabilities | - | - | - | -0.20M | -0.08M |
| Total cashflows from investing activities | - | - | - | -0.07M | -0.07M |
| Total cash from financing activities | 10.70M | 2.20M | 1.73M | 20.01M | 4.29M |
| Change to operating activities | - | - | - | -0.26M | -0.72M |
| Net income | -9.89M | -16.08M | -13.87M | -10.44M | -10.88M |
| Change in cash | 0.12M | -9.33M | -13.39M | 10.02M | -6.67M |
| Begin period cash flow | 1.05M | 10.38M | 23.77M | 13.76M | 20.43M |
| End period cash flow | 1.17M | 1.05M | 10.38M | 23.77M | 13.76M |
| Total cash from operating activities | -10.57M | -11.54M | -15.10M | -9.92M | -10.96M |
| Issuance of capital stock | 10.70M | 3.42M | 1.73M | 15.85M | 4.29M |
| Depreciation | 0.16M | 0.18M | 0.18M | 0.16M | 0.15M |
| Sale purchase of stock | - | - | - | - | 4.29M |
| Other cashflows from financing activities | - | 0.53M | -0.02M | 4.16M | - |
| Change to netincome | - | - | - | 0.82M | 0.58M |
| Capital expenditures | 0.00M | 0.00M | 0.02M | 0.07M | 0.07M |
| Cash flows other operating | - | - | - | - | -0.64M |
| Cash and cash equivalents changes | - | - | - | - | -6.67M |
| Change in working capital | 0.68M | 3.13M | -2.26M | -0.46M | -0.81M |
| Stock based compensation | 0.57M | 0.73M | 0.85M | 0.82M | 0.58M |
| Other non cash items | - | 0.50M | - | 10.90M | 5.15M |
| Free cash flow | -10.57M | -11.54M | -15.12M | -9.99M | -10.96M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BPTH Bio Path Holdings Inc |
- -% |
0.00 | - | 84.75 | 39.57 | 1.90 | 61.75 | 0.03 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
4710 Bellaire Boulevard, Bellaire, TX, United States, 77401
832 742 1357
1
| Name | Title | Year Born |
|---|---|---|
| Mr. Peter H. Nielsen MBA | Co-Founder, Chairman, CEO, Pres, CFO & Treasurer | 1949 |
| Mr. Douglas P. Morris | Co-Founder, Director of Investor Relations, Sec. & Director | 1956 |
| Mr. Anthony Price | Sr. VP of Fin., Accounting & Admin. | NA |
| Dr. Ana Tari Ashizawa Ph.D., MBA | Sr. VP of Research, Devel. & Clinical Design | NA |
| Dr. Alan MacKenzie Ph.D. | Consultant | NA |
| Dr. Thomas A. Walker Ph.D. | Consultant | NA |
| Dr. Jeffery Lancet M.D. | Consultant | NA |
| Ms. Victoria Lake Rac | Regulatory Consultant | NA |
| Mr. Peter H. Nielsen MBA | Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer | 1949 |
| Mr. Douglas P. Morris | Co-Founder, Director of Investor Relations, Secretary & Director | 1956 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...